查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
CRISPR 基因編輯市場：當前分析和預測 (2022-2028)
市場調查報告書
商品編碼
1260711

CRISPR 基因編輯市場：當前分析和預測 (2022-2028)

CRISPR Gene Editing Market: Current Analysis and Forecast (2022-2028)
出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 145 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

由於對新治療藥物的需求不斷增長，CRISPR 基因編輯市場預計將以 18% 左右的速度穩定增長。 CRISPR 基因編輯市場競爭激烈，有許多現有和新進入者。 市場上的主要參與者包括 Editas Medicine、CRISPR Therapeutics、Intellia Therapeutics 和 Caribou Biosciences。 這些公司提供各種 CRISPR 基因編輯產品和服務，包括研發、臨床試驗和商業化。 例如，2020 年 10 月，CRISPR Therapeutics 宣布啟動一項新的基因編輯計劃，用於治療遺傳性視網膜疾病 (IRD)。 該計劃旨在使用 CRISPR-Cas9 基因編輯來靶向和糾正導致失明的 IRD 的基因突變。

根據產品類型，市場分為 CRISPR 產品和 CRISPR 服務。 其中，由於對基因工程技術的需求不斷增加以及包括 CRISPR 基因編輯試劑盒在內的眾多尖端技術的發展，預計 CRISPR 產品類別在預測期內將實現高複合年增長率。 此外，可用於實現各種目標的增強型單個產品的可用性，例如更容易的基因敲除、選擇性基因組切割、減少脫靶切割、基因組工程和高特異性，這解釋了該細分市場的增長。

按應用分為農業、生物醫學（基因治療、藥物發現、診斷）、工業和其他。 其中，生物醫藥品類在2021年將佔據較大的市場份額。 生物醫藥行業是最早採用CRISPR基因編輯技術的行業之一。 這是因為技術有可能徹底改變遺傳疾病的治療方法。 此外，增加對 CRISPR 基因編輯技術研發的投資、早期採用和嚴格的監管標準使生物醫藥領域成為該領域增長的主要驅動力。

按最終用戶劃分，CRISPR 基因編輯市場分為學術機構和研究中心、生物技術公司、合同研究組織 (CRO) 以及製藥和生物製藥公司。 預計在預測期內，製藥和生物製藥類別將主導 CRISPR 基因編輯市場。 這主要是由於我們在藥物開發方面的專業知識，包括臨床前和臨床階段，我們在研發方面的大量投資以開發新療法，包括基於 CRISPR 的療法，以及基於 CRISPR 的新療法的成功開發。製藥和生物製藥公司已經建立了分銷可以支持該細分市場增長的網絡。

為了更好地了解 CRISPR 基因編輯行業的市場採用情況，將市場分為北美（美國、加拿大、北美其他地區）、歐洲（德國、英國、法國、西班牙、意大利、其他地區）歐洲）、亞太地區（（中國、日本、印度和亞太地區其他地區），以及在其他地區國家的全球業務。 在預測期內，北美預計將以顯著的複合年增長率增長。 這主要是由於該地區發達的醫療基礎設施和高技能的勞動力，為 CRISPR 基因編輯技術的開發和商業化提供了有利的環境。 該地區強大的研究生態系統，包括許多著名的學術研究機構，也為北美 CRISPR 基因編輯市場的增長做出了貢獻。

內容

第一章市場介紹

  • 市場定義
  • 主要目的
  • 利益相關者
  • 限制

第 2 章研究方法或假設

  • 研究過程
  • 調查方法
  • 受訪者簡介

第三章市場總結

第 4 章執行摘要

第 5 章 COVID-19 對 CRISPR 基因編輯市場的影響

第 6 章 CRISPR 基因編輯市場收入，2020-2028F

第 7 章產品類型的市場洞察

  • CRISPR 產品
    • 試劑盒和□
    • 圖書館
    • 設計工具、抗體
    • 其他
  • CRISPR 服務
    • gRNA 設計和載體構建
    • 細胞系和工程
    • 篩選服務
    • 其他

第 8 章市場洞察：按應用

  • 農業
  • 生物醫學（基因療法、藥物發現、診斷學）
  • 工業
  • 其他

第 9 章市場洞察：最終用戶

  • 學術機構和研究中心
  • 生物技術公司
  • 委託研究組織 (CRO)
  • 製藥和生物製藥公司

第 10 章市場洞察：按地區

  • 北美
    • 美國
    • 加拿大
    • 其他北美地區
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 世界其他地方

第 11 章 CRISPR 基因編輯市場動態

  • 市場驅動力
  • 市場挑戰
  • 影響分析

第 12 章 CRISPR 基因編輯市場機會

第13章CRISPR基因編輯市場趨勢

第14章需求側與供給側分析

  • 需求方分析
  • 供應方分析

第 15 章價值鏈分析

第16章價格分析

第 17 章戰略洞察

第 18 章衝突場景

  • 競爭格局
    • 波特的五力分析

第十九章公司簡介

  • CRISPR Therapeutics
  • Thermo Fisher Scientific Inc.
  • Synthego
  • System Biosciences, LLC
  • ToolGen, Inc.
  • Agilent Technologies, Inc.
  • Merck KGaA
  • Applied StemCell
  • GeneCopoeia, Inc.
  • Cellecta, Inc.

第20章 免責事項

簡介目錄
Product Code: UMHE211748

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) gene editing is a revolutionary new technology that allows scientists to precisely modify genes in living organisms. This technology has the potential to revolutionize the field of medicine and provide new treatments for a range of diseases and medical conditions, including genetic disorders, cancer, and infectious diseases. The market for CRISPR gene editing is growing rapidly, driven by the increasing demand for new and effective treatments for various diseases and conditions, as well as the growing interest in precision medicine and personalized treatments. The market is also being driven by advancements in the technology itself, which are making it increasingly accessible and cost-effective for researchers and companies to use.

The CRISPR gene editing market is expected to grow at a steady rate of around 18% owing to the growing need for novel therapeutics. The CRISPR gene editing market is highly competitive, with many established players and new entrants. Key players in the market include Editas Medicine, CRISPR Therapeutics, Intellia Therapeutics, and Caribou Biosciences. These companies offer a range of CRISPR gene editing products and services, including research and development, clinical trials, and commercialization. For instance, in October 2020, CRISPR Therapeutics announced the launch of a new gene-editing program for the treatment of inherited retinal diseases (IRDs). The program aims to use CRISPR-Cas9 gene editing to target and correct mutations in the genes responsible for IRDs, which can cause blindness

Based on product type, the market is segmented into CRISPR products and CRISPR services. Among these, the CRISPR products category is to witness higher CAGR during the forecast period owing to the rising demand for genetic engineering technologies, and the development of a large number of cutting-edge technologies, including CRISPR gene editing kits. Additionally, the availability of enhanced individual products that can be used to achieve a variety of goals, such as simpler gene knockouts, selective genome cleavage, less off-target cutting, genome engineering, and higher specificity, is accountable for the growth of this segment.

On the basis of application, the market is categorized into agricultural, biomedical (gene therapy, drug discovery, and diagnostics), industrial, and others. Among these, the biomedical category held a significant share of the market in 2021. The biomedical industry has been one of the earliest adopters of CRISPR gene editing technology. This is because technology has the potential to revolutionize the treatment of genetic disorders and diseases. Furthermore, growing investment in research and development in CRISPR gene editing technology, early adoption, and strict regulatory standards has made the biomedical category a key driver in the growth of the segment.

Based on end-user, the CRISPR gene editing market has been classified into academic institutes & research centers, biotechnology companies, contract research organizations (CROs), and pharmaceutical & biopharmaceutical companies. The pharmaceutical & biopharmaceutical companies category is expected to dominate the CRISPR gene editing market during the forecast period. This is mainly due to expertise in drug development, including the preclinical and clinical phases, large investment in research and development to develop new therapies, including CRISPR-based treatments, they have the necessary expertise in regulatory compliance, manufacturing, commercialization to successfully launch new CRISPR-based therapies, and pharmaceutical and biopharmaceutical companies have established distribution networks that can boost the growth of this segment.

For a better understanding of the market adoption of the CRISPR gene editing industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is anticipated to grow at a substantial CAGR during the forecast period. This is mainly due to the region having a well-developed healthcare infrastructure and a highly skilled workforce, providing a conducive environment for the development and commercialization of CRISPR gene editing technology. The region's strong research ecosystem, including many renowned academic and research institutions, also contributes to the growth of the CRISPR gene editing market in North America.

Some of the major players operating in the market include: CRISPR Therapeutics; Thermo Fisher Scientific Inc.; Synthego; System Biosciences, LLC; ToolGen, Inc.; Agilent Technologies, Inc.; Merck KGaA; Applied StemCell; GeneCopoeia, Inc.; Cellecta, Inc

TABLE OF CONTENTS

1 MARKET INTRODUCTION

  • 1.1. Market Definitions
  • 1.2. Main Objective
  • 1.3. Stakeholders
  • 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1. Research Process of the CRISPR Gene Editing Market
  • 2.2. Research Methodology of the CRISPR Gene Editing Market
  • 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE CRISPR GENE EDITING MARKET

6 CRISPR GENE EDITING MARKET REVENUE, 2020-2028F

7 MARKET INSIGHTS BY PRODUCT TYPE

  • 7.1. CRISPR Products
    • 7.1.1. Kits and Enzymes
    • 7.1.2. Libraries
    • 7.1.3. Design Tools, Antibodies
    • 7.1.4. Others
  • 7.2. CRISPR Services
    • 7.2.1. gRNA Design and Vector Construction
    • 7.2.2. Cell Line and Engineering
    • 7.2.3. Screening Services
    • 7.2.4. Others

8 MARKET INSIGHTS BY APPLICATION

  • 8.1. Agricultural
  • 8.2. Biomedical (Gene Therapy, Drug Discovery, and Diagnostics)
  • 8.3. Industrial
  • 8.4. Others

9 MARKET INSIGHTS BY END-USER

  • 9.1. Academic Institutes & Research Centres
  • 9.2. Biotechnology Companies
  • 9.3. Contract Research Organizations (CROs)
  • 9.4. Pharmaceutical & Biopharmaceutical Companies

10 MARKET INSIGHTS BY REGION

  • 10.1. North America
    • 10.1.1. U.S.
    • 10.1.2. Canada
    • 10.1.3. Rest of North America
  • 10.2. Europe
    • 10.2.1. Germany
    • 10.2.2. U.K.
    • 10.2.3. France
    • 10.2.4. Italy
    • 10.2.5. Spain
    • 10.2.6. Rest of Europe
  • 10.3. Asia-Pacific
    • 10.3.1. China
    • 10.3.2. Japan
    • 10.3.3. India
    • 10.3.4. Rest of Asia-Pacific
  • 10.4. Rest of World

11 CRISPR GENE EDITING MARKET DYNAMICS

  • 11.1. Market Drivers
  • 11.2. Market Challenges
  • 11.3. Impact Analysis

12 CRISPR GENE EDITING MARKET OPPORTUNITIES

13 CRISPR GENE EDITING MARKET TRENDS

14 DEMAND AND SUPPLY-SIDE ANALYSIS

  • 14.1. Demand Side Analysis
  • 14.2. Supply Side Analysis

15 VALUE CHAIN ANALYSIS

16 PRICING ANALYSIS

17 STRATEGIC INSIGHTS

18 COMPETITIVE SCENARIO

  • 18.1. Competitive Landscape
    • 18.1.1. Porters Fiver Forces Analysis

19 COMPANY PROFILED

  • 19.1. CRISPR Therapeutics
  • 19.2. Thermo Fisher Scientific Inc.
  • 19.3. Synthego
  • 19.4. System Biosciences, LLC
  • 19.5. ToolGen, Inc.
  • 19.6. Agilent Technologies, Inc.
  • 19.7. Merck KGaA
  • 19.8. Applied StemCell
  • 19.9. GeneCopoeia, Inc.
  • 19.10. Cellecta, Inc.

20 DISCLAIMER